93 related articles for article (PubMed ID: 8176940)
1. p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer.
Sasa M; Kondo K; Komaki K; Morimoto T; Monden Y
J Surg Oncol; 1994 May; 56(1):46-50. PubMed ID: 8176940
[TBL] [Abstract][Full Text] [Related]
2. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism.
Iacopetta B; Elsaleh H; Grieu F; Joseph D; Sterrett G; Robbins P
Diagn Mol Pathol; 2000 Mar; 9(1):20-5. PubMed ID: 10718209
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment.
Caleffi M; Teague MW; Jensen RA; Vnencak-Jones CL; Dupont WD; Parl FF
Cancer; 1994 Apr; 73(8):2147-56. PubMed ID: 8156519
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
6. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
7. p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma.
Pezeshki AM; Farjadian S; Talei A; Vasei M; Gharesi-Fard B; Doroudchi M; Ghaderi A
Cancer Lett; 2001 Aug; 169(1):69-75. PubMed ID: 11410327
[TBL] [Abstract][Full Text] [Related]
8. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
Effi AB; Aman NA; Koui BS; Koffi KD; Traoré ZC; Kouyate M
BMC Cancer; 2017 Feb; 17(1):115. PubMed ID: 28173783
[TBL] [Abstract][Full Text] [Related]
10. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
12. [Relation between grades of histologic differentiation and hormone receptors in breast cancer].
Nola N; Separović V; Sarcević B; Graf D; Petrinec Z; Matesa N; Kruslin B
Lijec Vjesn; 1995; 117(5-6):117-20. PubMed ID: 8600322
[TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
16. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 gene alterations in node-negative breast cancer.
Elledge RM; Fuqua SA; Clark GM; Pujol P; Allred DC; McGuire WL
Breast Cancer Res Treat; 1993; 26(3):225-35. PubMed ID: 8251647
[TBL] [Abstract][Full Text] [Related]
18. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer.
Umekita Y; Kobayashi K; Saheki T; Yoshida H
Jpn J Cancer Res; 1994 Aug; 85(8):825-30. PubMed ID: 7928628
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
20. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
